Filing Flows

Filing Flows › Harmony Biosciences Holdings (HRMY) › Q1 2025

Harmony Biosciences Holdings (HRMY) Q1 2025 earnings results (first quarter 2025)

10-Q filed May 6, 2025

Harmony Biosciences Holdings (HRMY) reported revenue of $185M for the first quarter 2025 (Q1 2025), +19% from a year earlier and -8% from the quarter before. Operating margin was 30.4%, net earnings $45.6M (24.7% of revenue).

Revenue$185M
Year over year+19%
Quarter over quarter-8%
Operating margin30.4%
Net earnings$45.6M

Harmony Biosciences Holdings, Q1 2025: revenue $185M (+20% year over year), operating margin 30.4%, net earnings $45.6M, operating cash flow $34.0M. The chart follows the revenue to costs, profit and cash.

Q1 2025AmountQ/QY/Y
Revenue$185M-8%+19%
Gross profit$153M+4%+20%
Operating profit$56.2M+0.9%+8%
Net earnings$45.6M-8%+19%
Operating cash flow$34.0M-55%+9%
Free cash flow$33.9M-55%+9%

What changed

Revenue was $184.7M in Q1 2025, up 19% year over year and down 8% from the previous quarter.

Gross margin was 82.7%, up 0.5 points from a year earlier. Operating profit was $56.2M, a 30.4% margin (down 3.2 points year over year). Of the extra revenue versus a year earlier, 14% reached operating profit, below the 34% margin then. Operating expenses grew 28% against revenue growth of 19%. The fastest-growing cost line was Research & development (+56%). Net earnings were $45.6M, up 19% year over year. The effective tax rate was 20.3%.

Operating cash flow was $34.0M (up 9% year over year), 75% of net earnings. Non-cash charges added back $6.0M of depreciation and amortization and $12.5M of share-based compensation. Working capital and other items used $30.0M. Capital expenditures of $128K left free cash flow of $33.9M.

Questions

What was Harmony Biosciences Holdings' revenue in the first quarter 2025?

Harmony Biosciences Holdings (HRMY) reported revenue of $185M for the first quarter 2025 (Q1 2025), +19% from a year earlier and -8% from the quarter before.

Was Harmony Biosciences Holdings profitable in the first quarter 2025?

Operating profit was $56.2M (30.4% of revenue) and net earnings $45.6M.

Open the interactive Sankey →

Source: Harmony Biosciences Holdings 10-Q on SEC EDGAR.